In this podcast, we speak with Rebecca Siegel, MPH, strategic director of surveillance information services in the Intramural Research Department at the American Cancer Society, and the lead author of the annual Cancer Statistics report that estimates the number of new cancer cases and deaths in the United States each year.
For the 25th consecutive year, overall cancer mortality rates in the United States have dropped. However, while many cancers have experienced declining rates of incidence and mortality, others have not. In addition, racial and socioeconomic factors continue to play a role in inequalities among cancer incidence and mortality rates.
In this podcast, we speak with Rebecca Siegel, MPH, strategic director of surveillance information services in the Intramural Research Department at the American Cancer Society, and the lead author of the annual Cancer Statistics report that estimates the number of new cancer cases and deaths in the United States each year.
You may need to log in to the website to access this podcast.
Listen above or through one of these podcast services:
Read more on cancer incidence and mortality:
Cancer Mortality Rate Drops for the 25th Consecutive Year, but Socioeconomic Gap Widens
Cancer Surpasses CVD as Leading Cause of Death in High-Income Counties
5-Year Survival Rates for Patients With Cancer Worldwide
After Two Decades of Decline, Prostate Cancer Mortality Rates Have Stabilized
As Cancer Incidence Changes, So Do Screening Recommendations
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More